As an adjuvant to allograft bone or as a replacement for harvested autograft, bone morphogenetic proteins (BMPs) appear to improve fusion rates after spinal arthrodesis in both animal models and humans, while reducing the donor-site morbidity previously associated with such procedures.
Bone morphogenetic proteins (BMPs) seem to be advantageous when used alongside allograft bone or as an alternative to autograft bone, resulting in enhanced fusion rates following spinal arthrodesis in both preclinical and clinical settings, while reducing donor-site issues associated with the procedure.